Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Long-Term Investments (2018 - 2022)

Historic Long-Term Investments for Arcturus Therapeutics Holdings (ARCT) over the last 5 years, with Q1 2022 value amounting to $131000.0.

  • Arcturus Therapeutics Holdings' Long-Term Investments fell 8950.32% to $131000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $131000.0, marking a year-over-year decrease of 8950.32%. This contributed to the annual value of $515000.0 for FY2021, which is N/A changed from last year.
  • As of Q1 2022, Arcturus Therapeutics Holdings' Long-Term Investments stood at $131000.0, which was down 8950.32% from $515000.0 recorded in Q4 2021.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Long-Term Investments peaked at $1.2 million during Q1 2021, and registered a low of $100000.0 during Q1 2020.
  • In the last 5 years, Arcturus Therapeutics Holdings' Long-Term Investments had a median value of $303000.0 in 2019 and averaged $493111.1.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Long-Term Investments surged by 114800.0% in 2021 and then crashed by 8950.32% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Long-Term Investments (Quarter) stood at $288000.0 in 2018, then dropped by 8.68% to $263000.0 in 2019, then plummeted by 61.98% to $100000.0 in 2020, then surged by 415.0% to $515000.0 in 2021, then tumbled by 74.56% to $131000.0 in 2022.
  • Its last three reported values are $131000.0 in Q1 2022, $515000.0 for Q4 2021, and $670000.0 during Q3 2021.